00267 Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

Reference Article

Younis, B. M., Osman, M., Khalil, E. A. G., Santoro, F., Furini, S., Wiggins, R., Keding, A., Carraro, M., Musa, A. E. A., Abdarahaman, M. A. A., Mandefield, L., Bland, M., Aebischer, T., Gabe, R., Layton, A. M., Lacey, C. J. N., Kaye, P. M., & Musa, A. M. (2021). Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan. Molecular therapy : the journal of the American Society of Gene Therapy, 29(7), 2366–2377. https://doi.org/10.1016/j.ymthe.2021.03.020

Abstract

Post-kala-azar dermal leishmaniasis (PKDL) is a chronic, stigmatizing skin condition occurring frequently after apparent clinical cure from visceral leishmaniasis. Given an urgent need for new treatments, we conducted a phase IIa safety and immunogenicity trial of ChAd63-KH vaccine in Sudanese patients with persistent PKDL. LEISH2a (ClinicalTrials.gov: NCT02894008) was an open-label three-phase clinical trial involving sixteen adult and eight adolescent patients with persistent PKDL (median duration, 30 months; range, 6– 180 months). Patients received a single intramuscular vaccination of 1 X 1010 viral particles (v.p.; adults only) or 7.5 X 1010 v.p. (adults and adolescents), with primary (safety) and secondary (clinical response and immunogenicity) endpoints evaluated over 42–120 days follow-up. AmBisome was provided to patients with significant remaining disease at their last visit. ChAd63-KH vaccine showed minimal adverse reactions in PKDL patients and induced potent innate and cell-mediated immune responses measured by whole-blood transcriptomics and ELISpot. 7/23 patients (30.4%) monitored to study completion showed >90% clinical improvement, and 5/23 (21.7%) showed partial improvement. A logistic regression model applied to blood transcriptomic data identified immune modules predictive of patients with >90% clinical improvement. A randomized controlled trial to determine whether these clinical responses were vaccine-related and whether ChAd63-KH vaccine has clinical utility is underway.